Literature DB >> 8998143

Differentiating histologic malignancy of primary brain tumors: pentavalent technetium-99m-DMSA.

T Hirano1, H Otake, T Shibasaki, M Tamura, K Endo.   

Abstract

UNLABELLED: This study assessed pentavalent 99mTc-DMSA uptake in primary brain tumors and evaluated the relationship between retention and histologic malignancy.
METHODS: SPECT images of the brain were obtained at 30 min and 3 hr after intravenous administration of approximately 555 MBq 99mTc(V)-DMSA in patients with brain tumors. Sixty studies were performed in 57 patients and 63 lesions were demonstrated: 11 glioblastomas, 13 anaplastic astrocytomas (Grade 3), 11 astrocytomas (Grade 2), 18 meningiomas and 10 schwannomas. Uptake ratios, retention ratio and retention index were calculated and compared with tumor histology and malignancy grade.
RESULTS: Approximately 95% of both benign and malignant primary brain tumors were demonstrated by 99mTc(V)-DMSA SPECT images. False negative was noted in three cases. The early uptake ratios were closely related to the tumor vascularity but had no statistically significant difference in the tumor histology or histologic malignancy. The delayed uptake ratio, retention ratio and retention index were higher in the malignant tumors than the benign tumors.
CONCLUSION: Technetium-99m(V)-DMSA washout from the tumor was highly dependent upon its histology and histologic malignancy. The delayed uptake ratio considerably reflected tumor histology and differentiated benign tumors from malignant tumors. The retention ratio and retention index significantly reflected tumor histology and histologic grade of primary brain tumors and clearly distinguished between benign and malignant tumors with statistically significant difference (p < 0.05). These results could suggest the clinical utility of 99mTc(V)-DMSA in imaging primary brain tumors and differentiating their histological malignancy grade noninvasively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8998143

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Classic tumour imaging agents for glioma evaluation: 99mTc-tetrofosmin.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Konstantinos S Polyzoidis; Andreas D Fotopoulos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

2.  Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results.

Authors:  Amr Amin; Hosna Moustafa; Ebaa Ahmed; Mohamed El-Toukhy
Journal:  J Neurooncol       Date:  2011-09-13       Impact factor: 4.130

3.  Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines.

Authors:  Delphine Denoyer; Nathalie Perek; Nathalie Le Jeune; Jérôme Cornillon; Francis Dubois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-23       Impact factor: 9.236

4.  Influence of Pi3-K and PKC activity on 99mTc-(V)-DMSA uptake: correlation with tumour aggressiveness in an in vitro malignant glioblastoma cell line model.

Authors:  Nathalie Le Jeune; Nathalie Perek; Francis Dubois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

5.  Optimizing dual-time and serial positron emission tomography and single photon emission computed tomography scans for diagnoses and therapy monitoring.

Authors:  Joseph A Thie
Journal:  Mol Imaging Biol       Date:  2007 Nov-Dec       Impact factor: 3.488

6.  Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.

Authors:  Spyridon Tsiouris; Ioannis Pirmettis; Theodoros Chatzipanagiotou; Nikolaos Ptohis; Vassilios Papantoniou
Journal:  J Neurooncol       Date:  2007-06-07       Impact factor: 4.130

7.  Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.

Authors:  Vassilios J Papantoniou; Michael A Souvatzoglou; Varvara J Valotassiou; Androniki N Louvrou; Constantina Ambela; John Koutsikos; Dimitrios Lazaris; Julie K Christodoulidou; Maria G Sotiropoulou; Maria J Melissinou; Aris Perperoglou; Spyridon Tsiouris; Cherry J Zerva
Journal:  Breast Cancer Res       Date:  2003-12-11       Impact factor: 6.466

Review 8.  Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy.

Authors:  Jaya Shukla; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2015 Oct-Dec

9.  Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.

Authors:  Vladimir R Vukomanovic; Milovan Matovic; Mirjana Doknic; Vesna Ignjatovic; Ivana Simic Vukomanovic; Svetlana Djukic; Miodrag Peulic; Aleksandar Djukic
Journal:  Nucl Med Commun       Date:  2019-01       Impact factor: 1.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.